This phase 2 study (N = 116) evaluated single-agent vosaroxin, a firstin-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. ) had the most favourable safety and efficacy profile, with faster haematological recovery (median 27 d) and lowest incidence of aggregate sepsis (24%) and 30-d (7%) and 60-d (17%) all-cause mortality; at this dose and schedule, CR and CR/CRp rates were 31% and 35%, median OS was 7Á7 months and 1-year OS was 38%. Overall, vosaroxin resulted in low early mortality and an encouraging response rate; vosaroxin 72 mg/m 2 d 1, 4 is recommended for further study in this population. Registered at www.clinicaltrials.gov: #NCT00607997.
therapy, typically 60-70% in younger patients, are <50% in patients >65 years of age (Appelbaum et al, 2006) . Among older patients who achieve remission, 85% relapse within 3 years, with most surviving <1 year . Treatment-related mortality among patients ≥70 years of age treated with intensive chemotherapy may be as high as 26% at 4 weeks (Kantarjian et al, 2006 (Kantarjian et al, , 2010 . Older patients considered to be high risk for toxicity or poor response often receive less intense chemotherapy regimens or supportive care; approximately 30% of older patients with AML receive standard induction regimens (Menzin et al, 2002) . Given ongoing demographic shifts in the US (Vincent et al, 2010) , the challenge of treating AML in older adults will continue to grow.
Vosaroxin is a first-in-class, non-anthracycline anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, thereby inducing DNA damage, G2 cell-cycle arrest and apoptosis (Hawtin et al, 2010a) . Vosaroxin causes site-selective DNA double-stranded breaks in G/C-rich sequences, similar to the DNA damage observed in prokaryotes treated with quinolone antibiotics (Hawtin et al, 2010a) . Compared with classic topoisomerase II-inhibiting agents in current clinical use, the activity of vosaroxin is more specific, resulting exclusively from DNA intercalation and topoisomerase II inhibition (Hawtin et al, 2010a,b) . Vosaroxin is minimally metabolized, thus avoiding formation of free radicals (Evanchik et al, 2009) or reactive oxygen species (Hawtin et al, 2010a) implicated in the cardiotoxicity of anthracyclines (Gewirtz, 1999; Minotti et al, 2004) . In addition, vosaroxin is not a substrate of P-glycoprotein receptor-mediated efflux , and its activity is independent of TP53 (Walsby et al, 2011) , both potential mechanisms of drug resistance. Given these differentiating characteristics, vosaroxin may offer improved efficacy and safety over other topoisomerase II inhibitors.
In a phase 1b study in patients with relapsed or refractory AML, single-agent vosaroxin demonstrated an acceptable safety profile and encouraging clinical activity (Lancet et al, 2011) . Vosaroxin was administered weekly for 3 weeks (maximum tolerated dose [MTD] 72 mg/m 2 ) and twice-weekly for 2 weeks (MTD 40 mg/m 2 ). The dose-limiting toxicity was oral mucositis (stomatitis); other toxicities included infection, febrile neutropenia and reversible gastrointestinal (GI) events. Here, we report the results of the REVEAL-1 study (Response Evaluation of Vosaroxin in Elderly AML), a dose regimen optimization study assessing the efficacy and safety of single-agent vosaroxin in patients ≥60 years of age with newly diagnosed AML and an additional risk factor or adverse prognostic feature.
Patients and methods

Study design
This open-label, multicentre, phase 2 study evaluated the efficacy and safety of three vosaroxin treatment schedules in sequentially enrolled cohorts- 
Treatment
Patient cohorts were enrolled sequentially, first in Schedule A, which was the MTD for weekly dosing determined previously (Lancet et al, 2011) . Based on a preliminary safety review of Schedule A, Schedule B was added. This dosing regimen eliminated the third vosaroxin dose, reducing the total dose administered per cycle and shortening the duration of treatment to 8 d. Subsequently, Schedule C was added, to assess whether dose intensification, relative to Schedule B, might improve antileukaemic activity without losing the tolerability of the 2-dose schedule; two doses (72 and 90 mg/m 2 ) were evaluated for this schedule.
Vosaroxin was administered as a short (≤10 min) intravenous infusion. Patients could receive up to four treatment cycles. Patients with a reduction in bone marrow blast count or stable disease and no persistent, clinically significant nonhaematological adverse event (AE) after the first induction cycle were eligible for reinduction, to be initiated no earlier than day 15 and no later than day 57. Patients with CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) after induction/reinduction therapy were eligible for 1-2 consolidation cycles.
Supportive care
Patients received transfusion of blood products in accordance with institutional guidelines. After a preliminary review of safety data for patients in Schedule A, the concomitant use of prophylactic antibiotics, antifungal agents and antiviral agents according to institutional protocols was encouraged in Schedule B and C cohorts. Use of growth factors according to national guidelines was permitted.
Safety and efficacy assessments
For each successive cohort, the efficacy and safety of the regimen at a particular dose and schedule were assessed. Safety was assessed at baseline and throughout the study to identify changes from baseline and determine the incidence and severity of AEs, which were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (v3.0) (http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf).
Bone marrow biopsy or aspiration was performed at screening, on day 15 (AE1 d) of induction and reinduction cycles, at the time of haematological recovery (defined as absolute neutrophil count [ANC] >1000 cells/ll), and as clinically indicated. Responses were assessed based on International Working Group criteria (Cheson et al, 2003) . Differences in efficacy and safety between cohorts were assessed qualitatively, with real-time, investigator-driven review.
Endpoints
The primary endpoint was the combined complete remission (CR + CRp) rate for each vosaroxin treatment schedule. Secondary endpoints were: safety; rates of 30-and 60-d all-cause mortality; leukaemia-free survival (LFS; the time from response to relapse or death from any cause); overall survival (OS; the time from first vosaroxin infusion to death from any cause); and pharmacokinetics (PK). The time to haematological recovery was defined as the time from treatment initiation to the earliest visit at which the ANC was >1Á0 9 10 9 /l.
PK studies
Plasma PK profiles were evaluated on day 1 for all four regimens and on day 4 for Schedules C72 and C90. Standard PK parameters, including maximum concentration (C max ), terminal half-life (t 1/2 ), area under the concentration-versustime curve from time 0 to infinity (AUC 0-inf ), clearance (CL) and volume of distribution at steady state (V ss ), were derived from plasma concentration-versus-time data. Renal excretion of vosaroxin and its metabolites, N-desmethyl-vosaroxin and O-desmethyl-vosaroxin, was estimated from urine samples. See the Supporting Information for a full description of PK studies.
Statistics
The safety population comprised all enrolled patients who received any amount of vosaroxin; all safety and efficacy analyses were performed in the safety population. In Schedules A and B, the study design was based on a single-arm Green-Dahlberg 2-stage design (Green & Dahlberg, 1992) . A sample size of 30 patients in stage I and 25 additional patients in stage II provided 90% power (at a significance level of 0Á05) to reject the null hypothesis that the probability of remission (P) is ≤0Á30, if the true P is ≥0Á50. Schedule C employed a single-stage design with sample size goals of 30 and 20 patients for the C72 and C90 cohorts, respectively (see the Supporting Information for a full description of sample size considerations for each cohort). Descriptive statistics were used to summarize baseline patient characteristics, exposure, and safety and efficacy variables. Categorical and nominal variables were summarized by frequency and percentage. Continuous variables were summarized using standard summary statistics (N, mean, standard deviation, median, minimum and maximum). Ordinal variables were summarized by frequency distribution of scores and by summary statistics on the scores or shift tables, as appropriate. When appropriate, 95% confidence intervals (CIs) around point estimates were determined. Descriptive analyses of the time-to-event endpoints (LFS and OS) were performed using Kaplan-Meier methods.
Results
Patients and exposure
A total of 116 patients were enrolled across all schedules and doses and 113 received at least one dose of vosaroxin (safety population). Pretreatment characteristics of the patients are summarized in Table I . In all cohorts, the median patient age was ≥70 years and most patients (82%) had two or more adverse prognostic factors.
All 113 treated patients completed at least one induction cycle and 26 (23%) completed two induction/reinduction cycles. Of the 30 patients (27%) who received consolidation, 12 received one and 18 received the per-protocol maximum of two consolidation cycles. Ninety-five patients (84%) discontinued study treatment, due to treatment failure (n = 50), death (n = 21), unacceptable AE (n = 6), disease relapse (n = 5), physician's decision (n = 5) or other reason (n = 8).
Efficacy
Overall, 33 (29%) and 36 (32%) patients achieved CR and CR/CRp, respectively. Responses were observed across all schedules; the highest CR/CRp rates were observed with Schedules A (41%) and C72 (35%) ( Table II) The median OS in all patients was 7Á0 months (95% CI, 4Á0-9Á2 months) ( Fig 1A) ; median OS was 8Á6 months with Schedule A and 7Á7 months with Schedule C72 (Table II) . (Vardiman et al, 2009 ). **Cytogenetic data are missing for one patient in this cohort. Median OS (95% CI), months
11 ( With a minimum follow-up of 1 year, the 1-year survival rate was 38% with both Schedules A and C72. Among responders (CR and CRp, n = 36), the median OS was 15Á5 months (95% CI, 12Á7-18Á3 months) and the median LFS was 6Á5 months (95% CI, 4Á9-9Á8 months) (Fig 1B) .
Safety
Treatment-emergent AEs are summarized in Table III . Grade 3 or 4 AEs were predominantly haematologic and included thrombocytopenia (59%), febrile neutropenia (50%) and anaemia (49%). The incidence of grade 3/4 infections was higher with Schedule A (76%) than with the other 3 schedules (B: 57%; C72: 48%; C90: 55%). Grade ≥3 sepsis (aggregate of sepsis, bacteraemia, fungaemia and viraemia) occurred in 39% of patients; the frequency of sepsis was lowest in patients in the Schedule C72 cohort. The most frequent nonhaematological AEs of any grade included GI disorders (diarrhoea 74%, nausea 70%, oral mucositis/stomatitis 60%) and metabolic disorders (hypokalaemia 62%, anorexia 59%, hypomagneseamia 43%). The incidences of any-grade diarrhoea, oral mucositis/ stomatitis, hypokalaemia and anorexia were lower with Schedules B and C than with Schedule A. Ninety-one patients (81%) had ≥1 serious AE (SAE). The most common SAEs included pneumonia (24%), febrile neutropenia (21%) and oral mucositis/stomatitis (10%). Of 113 patients treated, 103 died over the study duration. Most deaths (78%; n = 80) were due to progressive disease Anorexia  72  28  51  9  59  10  55  0  59  12  Hypokalaemia  72  41  54  20  59  21  65  15  62  25  Hypomagnesaemia  52  3  40  0  48  0  30  0  43  1  Hypophosphataemia  45  24  23  3  21  7  25  15  28  12  Dehydration  28  14  20  0  10  3  25  15  20  7  Hypocalcaemia  28  14  14  6  31  10  20  10  23  10  Hyperglycaemia  10  7  20  6  21  10  15  5  17  7  Nervous system disorders  Headache  35  0  26  3  31  3  10  0  27  2  Dizziness  21  0  20  0  24  0  20  0  21  0  Psychiatric disorders  Insomnia  41  0  37  0  38  0  15  0  35  0  Confusional state  28  14  26  0  28  3  10  5  24  5  Anxiety  24  0  40  0  41  3  20  0  33  1  Respiratory, thoracic, and mediastinal disorders  Cough  45  0  31  0  38  0  25  0  35  0  Dyspnea  38  24  40  9  38  3  25  15  36  12  Rales  35  0  23  0  7  0  15  0  20  0  Epistaxis  24  0  37  0  28  7  25  0  29  2  Pleural effusion  24  0  23  9  38  0  10  0  25  3  Hypoxia  10  7  17  14  21  3  10  0  15  7  Skin and subcutaneous tissue disorders  Alopecia  41  0  23  0  45  0  25  0  34  0  Petechiae  28  0  31  0 ( Table IV) . Across the entire population, 30-and 60-d allcause mortality rates were 12% and 31%, respectively. Early mortality was lowest with Schedule C72: 30-and 60-d mortality rates were 7% and 17%, respectively.
PK analyses
Plasma PK profiles were evaluated in 33 patients; Table V summarizes PK parameters by patient cohort. After a single dose, plasma vosaroxin concentrations declined in a biphasic manner with a short initial distribution phase, followed by a prolonged elimination phase. Across all cohorts, the average Rash  24  0  23  0  35  3  15  0  25  1  Vascular disorders  Hypotension  38  17  31  3  35  0  30  15  34  8  Hypertension  21  10  11  9  10  3  0  0  12  6 *72 mg/m 2 on days 1, 8, and 15. †72 mg/m 2 on days 1 and 8. ‡72 mg/m 2 on days 1 and 4. §90 mg/m 2 on days 1 and 4. ¶Aggregate sepsis includes sepsis, bacteraemia, viraemia and fungaemia, and represents 32 preferred terms; aggregate infections represent 30 preferred terms; aggregate pneumonia represents 10 preferred terms. **Includes 1 or more grade 5 events. Grade 5 aggregate sepsis was observed with schedules A (n = 4), B (n = 3), and C90 (n = 2); grade 5 aggregate pneumonia was observed with Schedules A (n = 1), B (n = 1), and C90 (n = 2); grade 5 aggregate infection was observed with Schedule B (n = 1). dose levels studied, CL was independent of age. Vosaroxin CL on day 1 was significantly higher in men than in women (P = 0Á0008), which may be related to a trend toward increased CL with greater body weight and greater body surface area. The average renal excretion of vosaroxin and its metabolites over 4 d was <5% of the total vosaroxin dose infused, indicating that vosaroxin CL is non-renal.
Discussion
REVEAL-1 evaluated the activity and tolerability of singleagent vosaroxin in previously untreated AML patients ≥60 years of age with ≥1 additional risk factor. Median patient age was 75 years and most patients (82%) had ≥2 risk factors. Complete remissions were observed across all treatment schedules and risk factors. Overall, vosaroxin produced a CR/CRp rate of 32%, with a 1-year OS rate of 34% (median OS 7Á0 months). Although most remissions (78%) were achieved during the first induction cycle, 29% of patients who received a second induction cycle achieved CR or CRp, underscoring the value of reinduction. Relative to weekly dosing for 3 weeks (Schedule A; days 1, 8, 15), tolerability of weekly dosing for 2 weeks (Schedule B; days 1, 8) appeared to be superior, with a notable decrease in the incidence of grade ≥3 sepsis (52% vs. 34%) and infections (21% vs. 6%), and reduced 30-d all-cause mortality (21% vs. 9%); however, the CR/CRp rate was lower with Schedule B than with Schedule A (26% vs. 41%) and 60-d all-cause mortality was comparable between Schedules B and A (37% vs. 38%). Although the number of patients in each cohort was too small to allow formal comparison, these observations suggest that elimination of the third weekly dose improved tolerability. However, the decreased dose intensity with Schedule B may have been associated with reduced antileukaemic activity.
The Schedule C72 cohort demonstrated the best risk-benefit profile, indicating that two doses of vosaroxin delivered over a short period of time may be most beneficial. With this schedule, time to recovery of both neutrophils and platelets was improved by more than 7 d compared with Schedules A and B, and the incidence of grade ≥3 aggregated sepsis was lowest (24%). The tolerability of Schedule C72 is particularly reflected in the low 30-d (7%) and 60-d (17%) all-cause mortality. In this cohort, CR and CR/CRp rates were 31% and 35%, median OS was 7Á7 months and 1-year OS was 38%. Outcomes were not improved by increasing the Schedule C dose to 90 mg/m 2 , which was associated with increased incidences of grade ≥3 aggregate sepsis (45%) and 60-d mortality (30%). The efficacy and mortality observed in this study, particularly in the Schedule C72 cohort, are consistent with the findings of two large, retrospective analyses of other chemotherapy induction regimens in previously untreated elderly patients with AML (Appelbaum et al, 2006; Kantarjian et al, 2006) , despite the fact that patients included in REVEAL-1 were required to have at least one unfavourable prognostic factor in addition to age ≥60 years, making the REVEAL-1 cohort a poor-risk population. In a review of patients treated with intensive multi-agent chemotherapy at a single centre from 1980 to 2004, Kantarjian et al (2006) reported a CR rate of 45% in patients ≥65 years of age, with an 8-week allcause mortality of 29%. Appelbaum et al (2006) compared treatment outcomes by age group in a retrospective analysis of five clinical studies; the CR rate for patients ≥66 years was 38% and the 30-d all-cause mortality was 19%.
A number of other agents are under investigation for the treatment of ageing patients with AML, including the cytotoxic agents decitabine (Blum et al, 2010; Kantarjian et al, 2012a) and sapacitabine (Kantarjian et al, 2012b) . Decitabine demonstrated a generally acceptable toxicity profile in a phase 3 trial in patients ≥65 years with intermediate-or poor-risk cytogenetics (30-and 60-d mortality rates of 9% and 20% respectively), but was associated with a lower response rate (18% CR/CRp) and longer time to response (median 4Á3 months) than observed in the current study (Kantarjian et al, 2012a) ; in a phase 2 study, low-dose decitabine over a 10-d period produced promising results (47% CR rate and 15% 8-week mortality), although other than age, patients were not required to have additional risk factors as in REVEAL (Blum et al, 2010) . In a phase 2 study comparing three dose regimens of sapacitabine in patients ≥70 years, an overall CR/CRp/CRi rate of 15% was observed, with 30-and 60-d mortality rates of 13% and 26% (Kantarjian et al, 2012b) . Each agent had an acceptable safety profile. Because older patients often have comorbidities, the safety profile of an agent is a key consideration in treatment choice. Vosaroxin could therefore represent an important, efficacious and tolerable therapeutic option for patients ≥60 years of age with poor-risk AML for whom standard intensive chemotherapy regimens may not be suitable. Vosaroxin is a structurally novel agent with a well-validated mechanism of action and toxicities that should be both familiar and acceptable to physicians who treat this large and vulnerable patient population.
On the basis of the safety and efficacy results of this study, the recommended single-agent dose regimen of vosaroxin in this population is 72 mg/m 2 on days 1, 4 (Schedule C72).
Compared with other doses and schedules tested, this regimen is associated with more rapid haematological recovery; an improved AE profile, including decreased rates of aggregated sepsis and infections; and low 30-and 60-d all-cause mortality.
In addition, response rates and OS were favourable with Schedule C72. Further evaluation of vosaroxin at this dose and schedule is warranted in a phase 3 randomized setting.
